WHAT IS CLAIMED IS:

1. An antibody or antigen-binding fragment thereof that binds to OX40 (TNF Receptor Superfamily Member 4) comprising:

a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, and

a light chain variable region (VL) comprising CDRs 1, 2, and 3,

wherein the VH CDRs 1, 2, and 3 amino acid sequences and the VL CDRs, 1, 2, and 3 amino acid sequences are selected from the group consisting of:

(1) the VH CDRs 1, 2, 3 sequences are set forth in SEQ ID NOs: 1, 2, 3, respectively, and the VL CDRs 1, 2, 3 sequences are set forth in SEQ ID NOs: 4, 5, 6, respectively;

(2) the VH CDRs 1, 2, 3 sequences are set forth in SEQ ID NOs: 7, 8, 9, respectively, and the VL CDRs 1, 2, 3 sequences are set forth in SEQ ID NOs: 10, 11, 12, respectively;

(3) the VH CDRs 1, 2, 3 sequences are set forth in SEQ ID NOs: 13, 14, 15, respectively, and the VL CDRs 1, 2, 3 sequences are set forth in SEQ ID NOs: 16, 17, 18, respectively; and

(4) the VH CDRs 1, 2, 3 sequences are set forth in SEQ ID NOs: 19, 20, 21, respectively, and the VL CDRs 1, 2, 3 sequences are set forth in SEQ ID NOs: 22, 23, 24, respectively.

2. The antibody or antigen-binding fragment thereof of claim 1, wherein the VH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3 respectively, and the VL comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively; or the VH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 13, 14, and 15 respectively, and the VL comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively.

3. A nucleic acid comprising a polynucleotide comprising:

(1) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 53, 54, 55, or 79; and an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 56, 57, 58, or 80;

(2) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 59, 60, 61, or 81; and an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 62, 63, 64, 65, or 82;

(3) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NOs: 66, 67, 68, or 83; and an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NOs: 69, 70, 71, 72, or 84; or

(4) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 73, 74, 75, or 85; and an immunoglobulin light chain or a fragment thereof comprising a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NOs: 76, 77, 78, or 86.

4. A vector comprising the nucleic acids of claim 3.

5. A cell comprising the vector of claim 4.

6. A method of producing an antibody or an antigen-binding fragment thereof, the method comprising

(a) culturing the cell of claim 5 under conditions sufficient for the cell to produce the antibody or the antigen-binding fragment; and

(b) collecting the antibody or the antigen-binding fragment produced by the cell.

7. An antibody or antigen-binding fragment thereof that binds to OX40 comprising

a heavy chain variable region (VH) comprising an amino acid sequence that is identical to a selected VH sequence, and a light chain variable region (VL) comprising an amino acid sequence that is identical to a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following:

(1) the selected VH sequence is SEQ ID NO: 53, 54, 55, or 79, and the selected VL sequence is SEQ ID NO: 56, 57, 58, or 80;

(2) the selected VH sequence is SEQ ID NO: 59, 60, 61, or 81, and the selected VL sequence is SEQ ID NO: 62, 63, 64, 65, or 82;

(3) the selected VH sequence is SEQ ID NO: 66, 67, 68, or 83, and the selected VL sequence is SEQ ID NO: 69, 70, 71, 72, or 84; and

(4) the selected VH sequence is SEQ ID NO: 73, 74, 75, or 85, and the selected VL sequence is SEQ ID NO: 76, 77, 78, or 86.

8. The antibody or antigen-binding fragment thereof of claim 7, wherein

(1) the VH comprises the sequence of SEQ ID NO: 53 and the VL comprises the sequence of SEQ ID NO: 56;

(2) the VH comprises the sequence of SEQ ID NO: 55 and the VL comprises the sequence of SEQ ID NO: 58;

(3) the VH comprises the sequence of SEQ ID NO: 55 and the VL comprises the sequence of SEQ ID NO: 56; or

(4) the VH comprises the sequence of SEQ ID NO: 73 and the VL comprises the sequence of SEQ ID NO: 77.

9. An antibody or antigen-binding fragment thereof that binds to OX40, comprising a heavy chain variable region comprising VH CDRs 1, 2, 3, and a light chain variable region comprising VL CDRs 1, 2, 3, wherein

(1) the VH CDRs 1, 2, 3 are identical to complementarity determining regions in SEQ ID NO:55, and the VL CDRs 1, 2, 3 are identical to complementary determining regions in SEQ ID NO: 56;

(2) the VH CDRs 1, 2, 3 are identical to complementarity determining regions in SEQ ID NO: 59, and the VL CDRs 1, 2, 3 amino acid sequences are identical to complementary determining regions in SEQ ID NO: 62;

(3) the VH CDRs 1, 2, 3 are identical to complementarity determining regions in SEQ ID NO: 66, and the VL CDRs 1, 2, 3 are identical to complementary determining regions in SEQ ID NO: 69; or

(4) the VH CDRs 1, 2, 3 are identical to complementarity determining regions in SEQ ID NO: 73, and the VL CDRs 1, 2, 3 are identical to complementary determining regions in SEQ ID NO: 76.

10. An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof of any one of claims 1, 7 and 9 covalently bound to a therapeutic agent, wherein the therapeutic agent is a cytotoxic or cytostatic agent.

11. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1, 7 and 9, and a pharmaceutically acceptable carrier.

12. A composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1, 7 and 9 for use in the treatment of a cancer, wherein the cancer is selected from unresectable melanoma, metastatic melanoma, sarcoma, small cell lung cancer, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), melanoma, bladder, triple-negative breast cancer (TNBC), and colorectal carcinoma.